131I美妥昔单抗联合肝动脉化疗栓塞术治疗原发性肝癌的临床效果  

Clinical effect of 131I-Metuximab combined with hepatic arterial transcatheter arterial chemoembolization in the treatment of primary liver cancer

作　　者：万超 陈彪[1] 林丹丹[1] 何晓琴[1] 徐细明[1] WAN Chao;CHEN Biao;LIN Dandan;HE Xiaoqin;XU Ximing(Cancer Center,Renmin Hospital of Wuhan University,Hubei Province,Wuhan430060,China)

机构地区：[1]武汉大学人民医院肿瘤中心,湖北武汉430060

出　　处：《中国医药导报》2020年第35期99-103,共5页China Medical Herald

基　　金：国家自然科学基金资助项目(31971166)。

摘　　要：目的评估131I美妥昔单抗注射液(利卡汀)联合肝动脉经导管动脉栓塞化疗(TACE)治疗中晚期原发性肝癌的效果及安全性。方法选取武汉大学人民医院肿瘤中心2017年1月—2019年2月收治的中晚期肝癌患者45例,按治疗方式分为两组:A组15例,接受利卡汀联合TACE治疗;B组30例,接受单纯TACE治疗。治疗后对两组患者进行随访观察,比较两组客观缓解率(ORR)、疾病控制率(DCR)、无进展生存(PFS)时间、介入治疗相关不良反应、血液学毒性[白细胞(WBC)计数、血小板(PLT)计数]及肝功能[总胆红素(TB)、丙氨酸转氨酶(ALT)]损伤的发生率。结果两组ORR、DCR及PFS比较,差异均无统计学意义(均P>0.05)。在介入治疗相关不良反应方面,两组患者在发热、腹痛、恶心呕吐发生率方面比较,差异均无统计学意义(均P>0.05)。在血液学毒性方面,A组患者术后1周PLT计数明显低于B组,差异有统计学意义(P<0.05);两组术后1周WBC计数比较,差异无统计学意义(P>0.05);在肝功能方面,两组术后1周TB及ALT水平比较,差异无统计学意义(P>0.05)。以上不良反应多为Ⅰ~Ⅱ级,未发生与治疗药物相关的严重不良事件。结论利卡汀联合TACE治疗原发性肝癌患者的耐受性和安全性较好,但疗效尚需进一步验证。Objective To evaluate the efficacy and safety of 131I-Metuximab injection(Licartine)combined with hepatic artery transcatheter arterial chemoembolization(TACE)in the treatment of advanced primary liver cancer.Methods A total of 45 patients with advanced liver cancer who admitted to the Cancer Center of Renmin Hospital of Wuhan University from January 2017 to February 2019 were selected and divided into two groups according to the treatment method,15 cases in group A,receiving licartin combined with TACE treatment;30 cases in group B received TACE treatment alone.After treatment,patients of the two groups were followed up to observe,and the objective response rate(ORR),disease control rate(DCR),progress free survival(PFS)time,interventional treatment-related adverse reactions,hematological toxicity(white blood cell[WBC]count,platelet[PLT]count)and liver function damage[total bilirubin(TB),alanine transaminase(ALT)]rate were compared between the two groups.Results There were no significant differences in ORR,DCR and PFS between the two groups(all P>0.05).In terms of adverse reactions related to interventional therapy,there were no significant differences in the incidence of fever,abdominal pain,nausea and vomiting between the two groups(all P>0.05).In terms of hematological toxicity,the PLT count in group A was significantly lower than that in group B at one week after operation,and the difference was statistically significant(P<0.05).There was no statistically significant difference in WBC counts between the two groups at one week after surgery(P>0.05).In terms of liver function,there were no statistically significant differences in TB and ALT levels between the two groups at one week after surgery(P>0.05).The above-mentioned adverse reactions were mostly gradeⅠ-Ⅱ,and no serious adverse events related to the treatment drugs occurred.Conclusion Licartin combined with TACE for the treatment of patients with primary liver cancer is well tolerated and safe,but the efficacy needs further verification.

关 键 词：原发性肝癌 经肝动脉化疗栓塞术 131I美妥昔单抗 近期疗效 不良反应 

分 类 号：R735.7[医药卫生—肿瘤]